Castle Biosciences (NASDAQ:CSTL) CFO Frank Stokes sold 26,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $49.52, for a total value of $1,287,520.00.
NASDAQ CSTL traded down $0.44 on Wednesday, hitting $48.04. The company’s stock had a trading volume of 168,524 shares, compared to its average volume of 182,339. The firm has a market cap of $945.52 million, a PE ratio of 436.77 and a beta of 0.45. The company’s 50-day moving average is $44.34 and its 200 day moving average is $36.59. The company has a quick ratio of 6.87, a current ratio of 6.93 and a debt-to-equity ratio of 0.09. Castle Biosciences has a 1-year low of $15.26 and a 1-year high of $52.32.
Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.33. The business had revenue of $12.72 million during the quarter, compared to the consensus estimate of $9.15 million. Castle Biosciences had a return on equity of 1.83% and a net margin of 11.35%. On average, equities analysts expect that Castle Biosciences will post -0.11 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. Two Sigma Advisers LP boosted its holdings in Castle Biosciences by 5.9% in the second quarter. Two Sigma Advisers LP now owns 14,300 shares of the company’s stock valued at $539,000 after acquiring an additional 800 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Castle Biosciences in the 2nd quarter worth approximately $584,000. Principal Financial Group Inc. bought a new stake in shares of Castle Biosciences in the 2nd quarter valued at $999,000. ArrowMark Colorado Holdings LLC boosted its stake in shares of Castle Biosciences by 6.2% in the 2nd quarter. ArrowMark Colorado Holdings LLC now owns 93,975 shares of the company’s stock valued at $3,542,000 after purchasing an additional 5,452 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Castle Biosciences by 2.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 23,222 shares of the company’s stock worth $876,000 after buying an additional 620 shares during the period. 59.99% of the stock is currently owned by institutional investors.
About Castle Biosciences
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.